|
Clinical profile of patients |
||||
| All (n = 86) |
Revascularization (n = 35) |
No Revascularization (n = 51) |
p-value |
|
|
|
||||
| Age, years |
57 ± 12 |
58 ± 11 |
57 ± 14 |
0.32 |
| Gender, male |
73 (85%) |
32 (91%) |
41 (80%) |
0.16 |
| History of hypertension |
54 (63%) |
26 (74%) |
28 (55%) |
0.07 |
| History of HL |
59 (69%) |
25 (71%) |
34 (67%) |
0.64 |
| History of diabetes |
24 (28%) |
11 (31%) |
13 (25%) |
0.55 |
| History of smoking |
26 (30%) |
12 (34%) |
14 (27%) |
0.50 |
| Beta Blocker Use |
62 (78%) |
27 (90%) |
35 (71%) |
0.06 |
| Ace-I or ARB Use |
45 (57%) |
17 (57%) |
28 (57%) |
0.36 |
| Coronary anatomy, n (%) |
||||
| 1 vessel disease |
13 (15%) |
3 (9%) |
10 (20%) |
0.16 |
| 2 vessels disease† |
24 (28%) |
7 (21%) |
17 (33%) |
0.17 |
| 3 vessels disease |
49 (57%) |
25 (71%) |
24 (47%) |
0.02 |
| ICD placement (%) |
31 (36%) |
8 (23%) |
24 (47%) |
0.02 |
| Scar volume (cm3) |
13.7 ± 12.7 |
14.5 ± 12.0 |
13.1 ± 13.3 |
0.60 |
| Scar % of myocardium (%) |
8.3 ± 6.9 |
9.2 ± 7.6 |
7.8 ± 6.3 |
0.37 |
| LVEF (%) |
26 ± 12 |
29 ± 13 |
24 ± 11 |
0.10 |
| LVEDV (ml%) |
231 ± 83 |
230 ± 97 |
232 ± 73 |
0.88 |
| LVESV (ml%) |
177 ± 83 |
173 ± 96 |
180 ± 74 |
0.69 |
| LVED mass/volume (g/ml) |
0.79 ± 0.30 |
0.83 ± 0.28 |
0.77 ± 0.31 |
0.22 |
| Ant, sep infarct lesion |
55 (64%) |
23 (66%) |
32 (63%) |
0.78 |
| Lat infarct lesion |
40 (47%) |
16 (46%) |
24 (47%) |
0.53 |
| Inf infarct lesion |
63 (73%) |
25 (71%) |
38 (75%) |
0.75 |
| Cardiovascular events |
33 (38%) |
16 (46%) |
17 (33%) |
0.24 |
|
Values are expressed as a mean ± SD. HL = hypercholesterolemia; Ace-I = Angiotensin Converting Enzyme – Inhibitor, ARB = Angiotensin Receptor Blocker ICD = implantable cardiac defibrillator; LVEF = left ventricular ejection fraction; LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; † 2 vessel disease include P-LAD or LMT. | ||||
Yokota et al. Journal of Cardiovascular Magnetic Resonance 2008 10:17 doi:10.1186/1532-429X-10-17 |
||||